LEGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Legend Biotech Corp (LEGN) is not a strong buy at the moment for a beginner investor with a long-term focus. The stock shows mixed signals with no immediate positive catalysts, declining analyst sentiment, and financial performance challenges. While the long-term growth potential exists, the current price trend and lack of strong trading signals suggest holding off on investment for now.
The MACD is positive but contracting, RSI is neutral at 60.129, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of $19.274, with key resistance at $20.81 and support at $17.739. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Some analysts believe the stock is undervalued and that market concerns about competition may be overdone.
Recent downgrades and price target reductions from multiple analysts due to competition concerns, sluggish demand, and toxicity issues for Carvykti. Financial performance in Q3 2025 showed a significant drop in net income (-68.33% YoY) and EPS (-67.65% YoY).
In Q3 2025, revenue increased by 69.99% YoY to $272.33M, but net income dropped to -$39.69M (-68.33% YoY), and EPS fell to -$0.11 (-67.65% YoY). Gross margin also declined to 57.66%, down 11.81% YoY.
Analyst sentiment has turned negative recently, with multiple downgrades and price target reductions. Concerns about competition, toxicity issues, and slower-than-expected uptake of Carvykti have been highlighted. However, some analysts still see long-term potential and undervaluation.
